Quantcast

Latest Mucopolysaccharidosis Stories

2010-04-19 08:00:00

NOVATO, Calif., April 19 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Firdapse(TM) (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010. Firdapse received marketing approval in the...

2010-04-01 08:00:00

NOVATO, Calif., April 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29, at 5:00 p.m. ET to discuss first quarter 2010 financial results. U.S. / Canada Dial-in Number: 866.804.6921 International Dial-in Number: 857.350.1667 Participant Code: 38613991 Replay Dial-in Number: 888.286.8010 Replay International Dial-in Number:...

2010-03-17 08:00:00

NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in Miami on Wednesday, March 24, 2010 at 9:30 a.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be...

2010-03-02 08:00:00

NOVATO, Calif., March 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Cowen and Company 30th Annual Health Care Conference in Boston on Tuesday, March 9, 2010 at 3:00 p.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on...

2010-02-25 15:49:00

NOVATO, Calif., Feb. 25 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has partnered with industry and patient advocacy organizations in an international effort to raise awareness of rare diseases which affect nearly 30 million Americans and millions of others around the world. As part of this program, the company hosted a special event today at its Novato headquarters to honor patients and reaffirm its commitment to developing much-needed...

2010-02-24 10:48:00

NEW YORK, Feb. 24 /PRNewswire/ -- Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Genetic Disorder Tracker, a monthly longitudinal data release that captures commercial trends, on a worldwide basis, associated with the treatment of eight rare genetic disorders: Gaucher's disease, Fabry's disease, PKU, MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), Niemann-Pick disease and Pompe disease. Guidepoint's Genetic...

2010-02-23 15:00:00

NOVATO, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Financial Highlights ($ in millions, except per share data) Item FY 2009 FY 2008 Comparison Total BioMarin Revenue $324.7 9.5% increase Total Net Product Revenue $315.7 25.4% increase Naglazyme Net Product Revenue $168.7 27.1% increase Aldurazyme BioMarin Net Product Revenue* $70.2...

2010-02-04 15:06:00

NOVATO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced 2010 financial guidance. The reconciliation of the non-GAAP measures to the estimated GAAP net income is detailed in the table provided in the press release. 2010 Guidance Revenue Guidance ($in millions) Item 2010 Guidance 2009 Guidance (Most recent) Total...

2010-02-04 15:03:00

NOVATO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers. "The acquisition of LEAD Therapeutics will augment our...

2010-02-04 15:00:00

NOVATO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.